Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?

por Peters, Godefridus J., Giovannetti, Elisa, Honeywell, Richard J., Ciccolini, Joseph
Publicado 2019

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance

por de Klerk, Daniel J., Honeywell, Richard J., Jansen, Gerrit, Peters, Godefridus J.
Publicado 2018

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines

por Noordhuis, Paul, Laan, Adrianus C., van de Born, Kasper, Honeywell, Richard J., Peters, Godefridus J.
Publicado 2019

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine

por Adema, Auke D, Floor, Karijn, Smid, Kees, Honeywell, Richard J, Scheffer, George L, Jansen, Gerrit, Peters, Godefridus J
Publicado 2014

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

por Adema, Auke D., Smid, Kees, Losekoot, Nienke, Honeywell, Richard J., Verheul, Henk M., Myhren, Finn, Sandvold, Marit L., Peters, Godefridus J.
Publicado 2011

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

por Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Poel, Dennis, Peters, Godefridus J., Griffioen, Arjan W., Verheul, Henk M. W.
Publicado 2016

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance

por Honeywell, Richard J., Kathmann, Ietje, Giovannetti, Elisa, Tibaldi, Carmelo, Smit, Egbert F., Rovithi, Maria N., Verheul, Henk M.W., Peters, Godefridus J.
Publicado 2020

Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine

por Bijnsdorp, Irene V., Schwendener, Reto A., Schott, Herbert, Fichtner, Iduna, Smid, Kees, Laan, Adrie C., Schott, Sarah, Losekoot, Nienke, Honeywell, Richard J., Peters, Godefridus J.
Publicado 2009

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors

por Rovithi, Maria, Gerritse, Sophie L., Honeywell, Richard J., ten Tije, Albert J., Ruijter, Rita, Peters, Godefridus J., Voortman, Jens, Labots, Mariette, Verheul, Henk M.W.
Publicado 2019

RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the...

por Sarkisjan, Dzjemma, Julsing, Joris R., El Hassouni, Btissame, Honeywell, Richard J., Kathmann, Ietje, Matherly, Larry H., Lee, Young B., Kim, Deog J., Peters, Godefridus J.
Publicado 2020

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells

por Martens-de Kemp, Sanne R., Dalm, Simone U., Wijnolts, Fiona M. J., Brink, Arjen, Honeywell, Richard J., Peters, Godefridus J., Braakhuis, Boudewijn J. M., Brakenhoff, Ruud H.
Publicado 2013

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

por Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Publicado 2015

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasc...

por Gotink, Kristy J., Broxterman, Henk J., Honeywell, Richard J., Dekker, Henk, de Haas, Richard R., Miles, Kiersten M., Adelaiye, Remi, Griffioen, Arjan W., Peters, Godefridus J., Pili, Roberto, Verheul, Henk M.W.
Publicado 2014

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice

por Timmers, Lonneke, Boons, Christel C. L. M., Mangnus, Dirk, Van de Ven, Peter M., Van den Berg, Pieter H., Beeker, Aart, Swart, Eleonora L., Honeywell, Richard J., Peters, Godefridus J., Boven, Epie, Hugtenburg, Jacqueline G.
Publicado 2016

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function

por Van Der Steen, Nele, Keller, Kaylee, Dekker, Henk, Porcelli, Letizia, Honeywell, Richard J., Van Meerloo, Johan, Musters, René J. P., Kathmann, Ietje, Frampton, Adam E., Liu, Daniel S. K., Ruijtenbeek, Rob, Rolfo, Christian, Pauwels, Patrick, Giovannetti, Elisa, Peters, Godefridus J.
Publicado 2020

Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters

por van de Velde, Mirjam E., den Bakker, Emil, Blufpand, Hester N., Kaspers, Gertjan L., Abbink, Floor C. H., Kors, Arjenne W. A., Wilhelm, Abraham J., Honeywell, Richard J., Peters, Godefridus J., Stoffel-Wagner, Birgit, Buffart, Laurien M., Bökenkamp, Arend
Publicado 2021

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome

por Labots, Mariette, Pham, Thang V., Honeywell, Richard J., Knol, Jaco C., Beekhof, Robin, de Goeij-de Haas, Richard, Dekker, Henk, Neerincx, Maarten, Piersma, Sander R., van der Mijn, Johannes C., van der Peet, Donald L., Meijerink, Martijn R., Peters, Godefridus J., van Grieken, Nicole C.T., Jiménez, Connie R., Verheul, Henk M.W.
Publicado 2020

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

por van Linde, Myra E., Labots, Mariette, Brahm, Cyrillo G., Hovinga, Koos E., De Witt Hamer, Philip C., Honeywell, Richard J., de Goeij-de Haas, Richard, Henneman, Alex A., Knol, Jaco C., Peters, Godefridus J., Dekker, Henk, Piersma, Sander R., Pham, Thang V., Vandertop, William P., Jiménez, Connie R., Verheul, Henk M.W.
Publicado 2022